Photo of Oliver Hodgkiss

Oliver Hodgkiss

Oliver Hodgkiss advises clients in the life science sector on transactions at all stages of the product life-cycle. Oliver regularly advises on strategic collaborations, licence agreements and other intellectual property issues that arise during drug development and commercialisation.

Following the UK’s departure from the EU, the UK Government has been exploring ways to leverage its new regulatory freedoms. In particular, the life sciences sector has been a key Government priority. As early as January 2021, for example, the Government granted the MHRA powers to fast-track approvals for innovative medicines. More recently, two reports from Westminster bodies have proposed a new regulatory regime for so-called “nutraceuticals” (products that are part drug, part nutritional) to encourage investment.Continue Reading Growing calls for separate Nutraceutical regulation in the UK